WallStreetZenWallStreetZen

NASDAQ: ANEB
Anebulo Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their ANEB stock forecasts and price targets.

Forecast return on equity

Is ANEB forecast to generate an efficient return?

Company
-210.88%
Industry
265.17%
Market
229.18%
ANEB's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is ANEB forecast to generate an efficient return on assets?

Company
-191.89%
Industry
92.7%
ANEB is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

ANEB earnings per share forecast

What is ANEB's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$0.49
Avg 2 year Forecast
-$0.47
Avg 3 year Forecast
-$0.50

ANEB revenue forecast

What is ANEB's revenue in the next 3 years based on estimates from 4 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

ANEB vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ANEB$2.33N/AN/A
ATOS$0.74$5.88+694.99%Buy
ELDN$1.59$8.50+434.59%Strong Buy
SPRB$90.16$209.50+132.36%Buy
PLRX$1.54$3.00+94.81%Buy
View Top Biotech Stocks

Anebulo Pharmaceuticals Stock Forecast FAQ

What is ANEB's earnings growth forecast for 2026-2028?

(NASDAQ: ANEB) Anebulo Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.83%.

Anebulo Pharmaceuticals's earnings in 2025 is -$8,442,381.On average, 3 Wall Street analysts forecast ANEB's earnings for 2026 to be -$20,115,084, with the lowest ANEB earnings forecast at -$19,326,257, and the highest ANEB earnings forecast at -$20,706,704. On average, 3 Wall Street analysts forecast ANEB's earnings for 2027 to be -$19,276,956, with the lowest ANEB earnings forecast at -$18,520,997, and the highest ANEB earnings forecast at -$19,843,925.

In 2028, ANEB is forecast to generate -$20,534,149 in earnings, with the lowest earnings forecast at -$19,728,888 and the highest earnings forecast at -$21,138,094.

If you're new to stock investing, here's how to buy Anebulo Pharmaceuticals stock.

What is ANEB's revenue growth forecast for 2026-2029?

(NASDAQ: ANEB) Anebulo Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 103.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.64%.

Anebulo Pharmaceuticals's revenue in 2025 is $0.On average, 4 Wall Street analysts forecast ANEB's revenue for 2026 to be $0, with the lowest ANEB revenue forecast at $0, and the highest ANEB revenue forecast at $0. On average, 3 Wall Street analysts forecast ANEB's revenue for 2028 to be $0, with the lowest ANEB revenue forecast at $0, and the highest ANEB revenue forecast at $0.

In 2029, ANEB is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is ANEB's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: ANEB) forecast ROA is -191.89%, which is lower than the forecast US Biotechnology industry average of 92.7%.

What is ANEB's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: ANEB) Anebulo Pharmaceuticals's current Earnings Per Share (EPS) is -$0.23. On average, analysts forecast that ANEB's EPS will be -$0.49 for 2026, with the lowest EPS forecast at -$0.47, and the highest EPS forecast at -$0.50. On average, analysts forecast that ANEB's EPS will be -$0.47 for 2027, with the lowest EPS forecast at -$0.45, and the highest EPS forecast at -$0.48. In 2028, ANEB's EPS is forecast to hit -$0.50 (min: -$0.48, max: -$0.51).

What is ANEB's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: ANEB) forecast ROE is -210.88%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.